| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000024677 |
| Receipt No. | R000028391 |
| Official scientific title of the study | Safety of indocyanine green lymphography for evaluation of lymphedema |
| Date of disclosure of the study information | 2016/11/02 |
| Last modified on | 2018/06/30 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Safety of indocyanine green lymphography for evaluation of lymphedema | |
| Title of the study (Brief title) | Indocyanine green lymphography for lymphedema | |
| Region |
|
|
| Condition | ||
| Condition | lymphedema | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Indocyanine green lymphography (ICG)is applied to clinical widely as a liver function test.These days, ICG is performed for evaluation of lymphedema as a preoperative examination.However, the side effects of ICG are not examined. Then, we perform ICG for lyphedema under medical treatment insurance adaptation outside (patient own expense) and evaluated the safety. Specifically, we carry out observation of whethe the general side effects (shock, nausea, blood vessel pain, fever)of ICG occur.
|
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Check whether there are side effects (shock, nausea, blood vessel pain, fever) |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | We carry out local injection of ICG at dorsum of foot and the inside of foot joint intra- or subcutaneously. We trace the flow of ICG with an infrared observation camera. We carry out observation of whether side effects (shock, nausea, blood vessel pain, fever)happen. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The person by whom lymphedema continued three months or more and written consent was got. | |||
| Key exclusion criteria | Those who have the past of hypersensitivity to iodine. Those who are judged that experimental participation is difficul by moral condition. A pregnant woman, a nursing mother. Moreover, those possible of pregnancy. The person to whom the doctor judged participation of the final examination to be unsuitable. | |||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuhiro Toriyama |
| Organization | Nagoya City University Hospital |
| Division name | Plastic and reconstructive surgery |
| Address | 1-Kawasumi, MIzuho-cho, Mizuho-ku, Nagoya, Japan |
| TEL | 052-858-7514 |
| toriyama@med.nagoya-cu.ac.jp | |
| Public contact | |
| Name of contact person | Takahumi Uchibori |
| Organization | Nagoya City University Hospital |
| Division name | Plastic and reconstructive surgery |
| Address | 1-Kawasumi, MIzuho-cho, Mizuho-ku, Nagoya, Japan |
| TEL | 052-858-7514 |
| Homepage URL | |
| uchibori83@gmail.com | |
| Sponsor | |
| Institute | Nagoya city university hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nagoya City University Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028391 |